Prediabetes linked to excess glucagon in transgenic mice with pancreatic active AKT1

Toya M Albury-Warren¹, Veethika Pandey¹, Lina P Spinel¹, Michal M Masternak^{1,2} and Deborah A Altomare¹

¹Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, 6900 Lake Nona Boulevard, Orlando, Florida 32827, USA

²Department of Head and Neck Surgery, The Greater Poland Cancer Centre, 61-866 Poznan, Poland

Correspondence should be addressed to D A Altomare

Email
Deborah.Altomare@ucf.edu

Abstract

Protein kinase B/AKT has three isoforms (AKT1–3) and is renowned for its central role in the regulation of cell growth and proliferation, due to its constitutive activation in various cancers. AKT2, which is highly expressed in insulin-responsive tissues, has been identified as a primary regulator of glucose metabolism as *Akt2* knockout mice (*Akt2*^{−/−}) are glucose-intolerant and insulin-resistant. However, the role of AKT1 in glucose metabolism is not as clearly defined. We previously showed that mice with myristoylated *Akt1* (AKT1^{Myr}) expressed through a bicistronic *Pdx1-TetA* and *TetO-MyrAkt1* system were susceptible to islet cell carcinomas, and in this study we characterized an early onset, prediabetic phenotype. Beginning at weaning (3 weeks of age), the glucose-intolerant AKT1^{Myr} mice exhibited non-fasted hyperglycemia, which progressed to fasted hyperglycemia by 5 months of age. The glucose intolerance was attributed to a fasted hyperglucagonemia, and hepatic insulin resistance detectable by reduced phosphorylation of the insulin receptor following insulin injection into the inferior vena cava. In contrast, treatment with doxycycline diet to turn off the transgene caused attenuation of the non-fasted and fasted hyperglycemia, thus affirming AKT1 hyperactivation as the trigger. Collectively, this model highlights a novel glucagon-mediated mechanism by which AKT1 hyperactivation affects glucose homeostasis and provides an avenue to better delineate the molecular mechanisms responsible for diabetes mellitus and the potential association with pancreatic cancer.

Key Words

- insulin signaling
- glucagon
- glucose metabolism
- pancreas
- oncogenes

Journal of Endocrinology
(2016) 228, 49–59

Introduction

AKT, a serine/threonine kinase, is downstream of phosphatidylinositol-3-kinase (PI3K) and growth factor receptors (e.g. epidermal growth factor receptor), and is a hallmark signaling protein predominantly recognized for regulation of cell survival, growth, and proliferation. AKT signals through the phosphorylation and subsequent activation or inhibition of downstream substrates, such as

mammalian target of rapamycin complex 1 (mTORC1) or glycogen synthase kinase 3 beta (GSK-3beta), respectively (Hemmings & Restuccia 2012). AKT hyperactivation in various cancers has been studied (Altomare & Testa 2005, Cheung & Testa 2013), while its role in glucose metabolism has been noted but comparatively overlooked until analysis of AKT isoform knockout mice.

Although analogous in structure, AKT isoforms (AKT1, AKT2, and AKT3) are encoded by three different genes, which are differentially expressed in tissues and have varying functions (Hay 2011). While *Akt1* is ubiquitously expressed in mammalian tissues, it was initially deemed unnecessary for glucose homeostasis as *Akt1* knockout mice (*Akt1*^{-/-}) have impaired fetal and adulthood growth, but normal glucose tolerance and insulin signaling (Cho *et al.* 2001b). *Akt3* is primarily expressed in the brain and was also reported unnecessary for glucose homeostasis with *Akt3*^{-/-} mice exhibiting reduced brain size and weight, but normal glucose regulation (Tschopp *et al.* 2005). In contrast, *Akt2* is highly expressed in insulin responsive tissues and has been identified as a primary regulator of glucose metabolism, as *Akt2* knockout mice (*Akt2*^{-/-}) are prediabetic with insulin resistance, hyperinsulinemia and glucose intolerance (Cho *et al.* 2001a, Garofalo *et al.* 2003).

A role for AKT1 in glucose homeostasis became evident with the metabolic analysis of compound isoform knockout mice (Chen *et al.* 2009). Similar to *Akt2*^{-/-} mice, *Akt1*^{+/+}*Akt2*^{-/-}*Akt3*^{-/-} mice were mildly diabetic, suggesting that the loss of *Akt3* was inconsequential. Conversely, haploinsufficiency of *Akt1* in *Akt2*^{-/-} mice resulted in a more severe diabetic phenotype, characterized by fed and fasted hyperglycemia, glucose intolerance, insulin resistance, and hyperinsulinemia. Additional crosses of *Akt1*^{+/+}*Akt2*^{-/-} mice with mice haploinsufficient for tumor suppressor phosphatase and tensin homolog (*PTEN*^{+/-}), an upstream regulator of AKT activation, significantly improved glucose homeostasis and demonstrated the compensatory nature and importance of AKT1, contrary to previous reports (Cho *et al.* 2001b). Although AKT1 hyperactivation has been frequently observed in pancreatic cancers (Schlieman *et al.* 2003, Missiaglia *et al.* 2010), there are limited studies regarding AKT1 hyperactivation and glucose homeostasis, except for attempts to improve the success rates of human islet transplantation therapy for diabetic patients (Bernal-Mizrachi *et al.* 2001, Tuttle *et al.* 2001, Kushner *et al.* 2005, Stiles *et al.* 2006). Hyperactivation of AKT1 in pancreatic β -cells, via PTEN deletion (Kushner *et al.* 2005, Stiles *et al.* 2006) or in mice with a myristoylated *Akt1* (Bernal-Mizrachi *et al.* 2001, Tuttle *et al.* 2001) under expression of a rat insulin promoter (RIP), led to hypoglycemia, hyperinsulinemia and improved glucose tolerance, due to increased β -cell mass, size, and proliferation.

We recently characterized aged mice with myristoylated, membrane-bound *Akt1* (AKT1^{Myr}) expressed using the Pdx promoter (Albury *et al.* 2015) and found that

~25% of mice developed islet cell carcinomas after 1 year of age. Here we report that this strain of mice exhibit non-fasted hyperglycemia as early as weaning and fasted hyperglycemia by 20 weeks of age, thus presenting a potentially unique opportunity to study the mechanistic cross-talk between diabetes and cancer. We show that the pre-diabetic phenotype can be attributed to the *Akt1*^{Myr} transgene, as it is tetracycline-regulatable, and down-regulation of the *Akt1*^{Myr} transgene reduced the non-fasted and fasted hyperglycemia to WT levels. Collectively, metabolic characterization of the AKT1^{Myr} mice revealed a novel glucagon-mediated mechanism by which AKT1 hyperactivation affects glucose homeostasis.

Materials and methods

Animals

All mice were housed and handled according to protocols approved by the University of Central Florida (UCF) Institutional Animal Care and Use Committee at the AAALAC accredited UCF Lake Nona Animal Facility. Transgenic mice with activation of AKT1 (Pdx-tTA;TetO-MyrAkt1) were mated as previously described (Albury *et al.* 2015). At 3 weeks, the pups were weaned and tail-snipped for DNA extraction and genotyping, as previously described (Albury *et al.* 2015). Mice with TetO-MyrAkt1, but lacking the knock-in Pdx-tTA, were classified as normal or WT littermates. Mice with Pdx-tTA and TetO-MyrAkt1 were classified as AKT1^{Myr} mice having constitutively active AKT1 in the pancreas. Litters were placed on a standard control diet or a doxycycline diet (BioServ, Frenchtown, NJ, USA), which shuts off AKT1^{Myr} transgene expression. All mice were euthanized according to American Veterinary Medical Association guidelines.

Genotyping analysis

Primers for PCRs for AKT1^{Myr} mice were previously described (Albury *et al.* 2015). *Akt2*^{KO} mice were obtained from J R Testa (Fox Chase Cancer Center, Philadelphia, PA, USA), and PCR primers detected the presence of WT or knockout *Akt2* (5'-GATGAAGTTCAGGGTCAGCTT-3'; 5'-AGAGCTTCAGTGGATAGCCTA-3'; and 5'-TCTCTGTCACCTCCCCATGAG-3').

Histological analysis

Pancreatic tissue was fixed in 10% neutral buffered formalin (Surgipath Leica, Buffalo Grove, IL, USA) and embedded in paraffin for sectioning and processing as

previously described (Albury *et al.* 2015). Slides were stained for hematoxylin and eosin (Surgipath) or immunohistochemistry using the Polymer Refine Detection reagents (Leica) on the Bond-Max immunostainer (Leica). Antigen retrieval was optimized using sodium citrate (pH 6) or EDTA (pH 9) buffers (Leica). The following antibodies were used: phospho-Akt Ser473 (GeneTex, Irvine, CA, USA), also phospho-mTor Ser2448, phospho-S6 Ser235/236, glucagon, and insulin (all from Cell Signaling Technology, Danvers, MA, USA). All slides processed on the immunostainer were run with a negative control, which was treated with antibody diluent instead of the primary antibody, to ensure antibody specificity. Images were taken using a Leica DM 2000 microscope with 5 $\times$, 10 $\times$, or 40 $\times$ objectives. Islet size was measured in the whole pancreas of three mice per genotype. The mice selected had no significant lesions at the time of necropsy, as described by a pathologist. The pancreas was sectioned into 5 μ m sections and every 25th section was H&E stained. A total of 50 islets from three sections were analyzed per mouse. Islet diameter was determined using measuring tools available on an Axio Imaging System (Zeiss, Oberkochen, Germany).

Blood glucose measurement

Blood glucose levels were measured using a Contour Glucometer (Bayer) at weaning, 5, 7, 9, and 12 weeks. Weaning was at 3 weeks of age. Blood glucose levels were measured randomly, between 0900 and 1000 h, or after an overnight fast.

Glucose tolerance test

Mice were fasted overnight, weighed (g), i.p. injected with 2 g/kg D-glucose (Fisher, Waltham, MA, USA) and blood glucose tested with a glucometer before injection, 15, 30, 45, 60, and 120 min after injection. Blood glucose (mg/dl) vs time (min) was plotted and the area under the curve was calculated using GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA). Blood was collected, via cheek bleeds, into serum collection tubes at 0 and 45 min after injection. The serum was separated and stored at -80°C until analysis with Mercodia Glucagon and Ultrasensitive Mouse Insulin ELISAs (Mercodia, Uppsala, Sweden). The homeostatic model assessment for insulin resistance (HOMA-IR; (fasted glucose $\times$ fasted insulin)/405) was calculated using the fasted blood glucose and fasted serum insulin levels acquired during the glucose tolerance test (GTT; Grote *et al.* 2013).

Insulin tolerance testing

Mice were fasted for 2 h, weighed (g), i.p. injected with 2 IU/kg porcine insulin (Sigma) and blood glucose tested with a glucometer before injection, 15, 30, 45, and 60 min after injection. Blood glucose (mg/dl) vs time (min) was plotted and the area under the curve was calculated (GraphPad Prism 5).

Insulin stimulation

Mice were fasted overnight, weighed (g), anesthetized using isoflurane and injected with porcine insulin (10 IU/kg; Sigma) or saline via the inferior vena cava. After 2 min, mice were euthanized and the following tissues were snap-frozen in liquid nitrogen: pancreas, liver, perigonadal adipose tissue, and skeletal muscle. Tissues were homogenized using 15 mg zirconium oxide beads (1.0 mm for skeletal muscle and 0.5 mm for adipose, liver, and pancreas) with the Bullet Blender Homogenizer BBX24 (Next Advance, Averill Park, NY, USA). Proteins were extracted for ELISA analysis for AKT, AKT (pS473), insulin receptor (IR), and IR (pY1158) (all from Invitrogen). Data was analyzed using a four-parameter algorithm to construct the best fitting curve.

Statistical analysis

Results are reported as mean $\pm$ s.e.m. Comparisons were made between two and more than two groups using unpaired or paired Student's *t*-tests and two-way ANOVA followed by Student's *t*-tests within groups, respectively. All analysis used GraphPad Prism 5 with significance accepted at a *P* value of <0.05 . Letters were used to illustrate significance, as multiple groups are being compared. Groups that do not share the same letter display a statistical significance of $P<0.05$.

Results

AKT1^{Myr} transgenic mice have tetracycline-regulatable AKT/mTOR pathway activation in the pancreas

The AKT1^{Myr} construct uses the *Pdx1* promoter, which is important for pancreas development *in utero* and postnatal β -cell maintenance (Holland *et al.* 2002), to drive the expression of myristoylated and therefore active *Akt1* within different pancreatic cell lineages. Expression of the *Akt1*^{Myr} transgene is inhibited in the presence of the tetracycline analogue doxycycline. Immunohistochemistry (Fig. 1A), using phospho-specific antibodies, validated increased phosphorylated or active

AKT1, along with its downstream substrates mTORC1 and S6, in the islets of AKT1^{Myr} mice given standard feed, as compared to WT mice on standard feed and doxycycline fed AKT1^{Myr} mice. To quantify this result, protein was extracted from insulin-stimulated pancreatic tissue and measured via ELISA (Fig. 1B), confirming significantly elevated ($P < 0.001$) AKT1 phosphorylation (Ser473) and thus activation in AKT1^{Myr} mice vs WT mice. Pancreatic levels of phosphorylated AKT1 (Ser473) were eight times greater in AKT1^{Myr} mice than WT mice, while phosphorylated AKT1 levels in doxycycline fed AKT1^{Myr} mice were equal to those of WT mice, confirming the ability of doxycycline to turn off the transgene. Doxycycline treatment began at weaning and continued for 2 weeks, which was sufficient to decrease the activation of the AKT/mTOR pathway to WT levels. There was no significant difference in total AKT between groups.

Reversible, non-fasted and fasted hyperglycemia in AKT1^{Myr} transgenic mice

At weaning, mice were tail snipped for genotyping and blood glucose tested. AKT1^{Myr} mice ($n = 10$), regardless of sex (Fig. 2G), had significantly higher ($P < 0.0001$) non-fasted blood glucose levels at weaning than WT littermates

(Fig. 2A). Non-fasted blood glucose levels were monitored biweekly for 9 weeks following weaning, and similarly, AKT1^{Myr} mice had significantly higher ($P = 0.0031$) non-fasted blood glucose levels at 12 weeks of age compared to WT mice (Fig. 2A).

To confirm that the non-fasted hyperglycemia was due to the *Akt1*^{Myr} transgene expression, doxycycline was administered to mice in order to turn off the transgene. Mating cages were arranged with half receiving standard feed and half receiving doxycycline feed for *in utero* exposure. Feeding regimens were continued at weaning and non-fasted blood glucose levels were monitored biweekly for 9 weeks. At weaning, the non-fasted blood glucose levels for AKT1^{Myr} mice on a standard diet were significantly higher ($P < 0.02$) than all other treatment groups. There was no significant difference between the AKT1^{Myr} mice on doxycycline and the WT mice on either diet, and the same pattern was observed at 12 weeks (Fig. 2B). With regard to overnight fasting, 12-week AKT1^{Myr} mice exhibited no significant difference in fasted glucose levels (Fig. 2C). However, aged AKT1^{Myr} exhibited fasted hyperglycemia, a more severe diabetic phenotype, by 5 months of age (Fig. 2D), which was also attenuated by doxycycline treatment. Weight (Fig. 2E) and food intake (Fig. 2F) did not differ among genotypes.

Figure 1

AKT1^{Myr} mice have doxycycline-regulatable AKT/mTOR pathway activation in the pancreas. Hyperactivation and decreased activation of the AKT/mTOR pathway in AKT1^{Myr} mice on regular chow diet and AKT1^{Myr} mice on doxycycline diet respectively, confirmed with: (A) immunostaining of representative pancreatic tissue using phospho-AKT (Ser473), phospho-mTOR (Ser2448), and phospho-S6 (Ser235/236) antibodies (40 $\times$ objective; scale bar 50 μ m) and (B) analysis of protein from pancreatic tissue using a phospho-AKT1 (Ser473) ELISA. Two-way ANOVA followed by Student's *t*-tests

within groups were used to analyze the data. Data represented as mean $\pm$ S.E.M. ($n = 5$). All phospho-AKT1 measurements were normalized to their total AKT measurements. Reg, regular chow diet; Dox, doxycycline diet. Letters were used to illustrate significance as multiple groups are being compared (see the 'Materials and methods' section for explanation). A full colour version of this figure is available at <http://dx.doi.org/10.1530/JOE-15-0288>.

Figure 2

AKT1^{Myr} mice have a reversible, fasted and non-fasted hyperglycemia. Blood glucose levels were measured with a glucometer (A) at weaning ($P < 0.0001$) and at 12 weeks ($P = 0.0031$). Weaning occurred at 3 weeks of age. To determine if the hyperglycemia exhibited at weaning was reversible, breeder mice were placed on a doxycycline diet to expose the pups *in utero*. Blood glucose levels were then measured (B) at weaning ($P < 0.02$) and at 12 weeks ($P \leq 0.003$). Mice were fasted overnight (16 h) to determine fasted blood glucose levels (C) at 12 weeks and (D) at 20 weeks ($P < 0.005$). (E) Weight was measured at weaning. At 12 weeks, mice were

housed individually and (F) food intake was measured daily for 4 days by weighing the food in the cage. Blood glucose levels, measured at weaning, were used to identify (G) sex differences. Two-way ANOVA followed by Student's *t*-tests within groups were used to analyze the data for A, B, C, D, E and G. Unpaired student's *t*-test was used for F. $n = 10$ for A, B, C, E, F and G except D ($n = 5$). Letters were used to illustrate significance as multiple groups are being compared (see the 'Materials and methods' section for explanation).

Glucose intolerance in AKT1^{Myr} transgenic mice due to insulin–glucagon imbalance

GTT was performed at 12 weeks ($n = 5$ males) to analyze the ability of AKT1^{Myr} mice to clear glucose from the blood. AKT1^{Myr} mice had a significantly higher ($P = 0.0049$) area under the curve (Fig. 3B)

compared to WT mice. The significantly elevated blood glucose levels began at 30-min post injection and continued for the duration of the test, signifying glucose intolerance (Fig. 3A).

Glucose intolerance in AKT1^{Myr} mice was compared and found to be similar to the well-established, prediabetic *Akt2*-null mouse model (AKT2^{KO}; Fig. 3C). However,

Figure 3

Glucose intolerance in AKT1^{Myr} mice due to insulin–glucagon imbalance. Glucose tolerance testing (GTT; $n=5$) was performed at 12 weeks comparing (A) WT and AKT1^{Myr} (MYR AKT1) mice and (C) WT, MYR AKT1, and Akt2^{-/-} (AKT2 KO) mice ($*P<0.05$). (B) Area under the curve. Data represented as mean $\pm$ S.E.M. ($P=0.0049$). Blood was collected, via cheek bleeds, at the 0- and 45-min time points to analyze serum (D) insulin and (E) glucagon levels using ELISAs. Insulin and glucagon values are also provided in Table 1. (F) Immunostaining of pancreatic tissue using

insulin and glucagon antibodies (objective 40×; scale bar 50 µm). Unpaired Student's *t*-tests were used to analyze differences in area under the curve and the GTT time points. Two-way ANOVA followed by Student's *t*-tests within groups were used to analyze the data for D and E. Letters were used to illustrate significance as multiple groups are being compared (see the 'Materials and methods' section for explanation). A full colour version of this figure is available at <http://dx.doi.org/10.1530/JOE-15-0288>.

serum insulin and glucagon levels, collected via cheek bleeding, revealed significant differences between AKT1^{Myr} and AKT2^{KO} mice. AKT2^{KO} mice had significantly ($P<0.02$) elevated insulin levels, which were evident before the glucose injection (0 min) and 45 min after the injection (Fig. 3D and Table 1). When compared to WT mice, AKT1^{Myr} mice did not initially (0 min) have elevated insulin levels. However, insulin levels were significantly ($P=0.009$) higher 45 min after the injection. Serum

glucagon levels in AKT2^{KO} mice were similar to WT mice (Fig. 3E and Table 1). However, AKT1^{Myr} mice had significantly ($P<0.05$) elevated fasted glucagon levels (0 min), which returned to WT levels by the 45-min time point. In addition to functional differences in pancreatic α -cells, AKT1^{Myr} mice had an altered distribution of α -cells throughout the pancreatic islets (Fig. 3F), typical of several diabetic murine models (Bates *et al.* 2008, Cummings *et al.* 2008).

Table 1 The average insulin and glucagon serum levels in WT, MYR AKT1, and AKT2 KO mice during the glucose tolerance test

Time post glucose injection	WT	MYR AKT1	AKT2 KO
Average insulin levels (µg/l)			
0 min	0.50	0.68	3.0 ^a ($P < 0.02$)
45 min	0.54	1.1 ^a ($P = 0.009$)	3.5 ^a ($P < 0.02$)
Average glucagon levels (pmol/l)			
0 min	1.38	2.18 ^a ($P < 0.05$)	0.84
45 min	1.42	1.02	1.16

^aIndicates a significant difference. The data in this table correspond to Fig. 3D and E.

Insulin resistance in the liver of AKT1^{Myr} transgenic mice

One week following the GTT, an insulin tolerance test ($n=5$ males) was performed to analyze the sensitivity of insulin-responsive tissues in AKT1^{Myr} mice. Area under the curve was calculated (Fig. 4A), in regard to blood glucose vs time, and was not significantly different when comparing AKT1^{Myr} mice and WT mice. However, at the 15-min time point the AKT1^{Myr} mice had significantly higher ($P=0.035$) blood glucose levels than the WT mice (Fig. 4B).

To further analyze insulin signaling, mice were injected with 10 IU/kg porcine insulin ($n=5$ males) or saline ($n=5$ males) via the inferior vena cava. Analysis of liver tissue revealed significantly decreased IR phosphorylation (Fig. 4C) in AKT1^{Myr} mice, compared to WT mice, despite no significant difference in IR levels. There were no differences in IR phosphorylation in adipose or muscle tissue (Fig. 4D and E). Calculation of the HOMA-IR confirmed insulin resistance in AKT1^{Myr} mice, as compared to WT mice (Fig. 4F).

Decreased pancreas and islet size, with aging, in AKT1^{Myr} mice

Pancreas size was measured upon euthanization and dissection using a digital scale ($n=5$) in 12-week- (Fig. 5A) and 16-month- (Fig. 5B) old mice. The pancreas size in the young AKT1^{Myr} mice was not significantly different. However, the pancreas size in the aged 16-month-old AKT1^{Myr} mice was significantly smaller ($P=0.0049$) than WT mice. Islet size ($n=50$ islets) was also measured at 12 weeks (Fig. 5C) and 16 months (Fig. 5D). Islet diameter was not significantly different in 12-week-old mice, but significantly decreased ($P=0.008$) in 16-month-old mice.

Discussion

In this study we characterized the early onset, prediabetic phenotype observed in AKT1^{Myr} mice and highlighted a novel mechanism by which AKT1 hyperactivation affects glucose homeostasis. AKT1^{Myr} mice, previously described for their aged onset islet cell carcinomas (Albury *et al.* 2015), have bicistronic regulation of myristoylated *Akt1* through a *Pdx1-TetA* and *TetO-MyrAkt1* system. This allows the expression of myristoylated, membrane-bound and thus activated AKT1 in the pancreas except in the presence of doxycycline, a tetracycline analogue. The *Pdx1* promoter, which is important for pancreas development *in utero* and postnatal β -cell maintenance (Holland *et al.* 2002), drives expression within the pancreatic progenitor cells, which eventually give rise to the endocrine cells (islets of Langerhans), exocrine cells (acini cells) and ductal cells of the pancreas (Hale *et al.* 2005). The hyperactivation of AKT1 throughout all cell types of the pancreas distinguishes this model from other constitutively active AKT1 mouse models, which use a RIP to drive expression in the β -cells (Bernal-Mizrachi *et al.* 2001, Tuttle *et al.* 2001). Additionally, the use of different tissue-specific promoters highlights the important role of expression patterns and cellular localization for AKT function.

The novelty of the glucose deregulation in AKT1^{Myr} mice is further elucidated when compared to the known, prediabetic *Akt2*-null mouse model (AKT2^{KO}). As previously reported, AKT2^{KO} mice have fasted and fed hyperglycemia beginning at 5 and 10 weeks in males and females, respectively (Garofalo *et al.* 2003). Male mice progress to a severe form of diabetes by 5 months of age and females remain prediabetic until 12 months of age (Cho *et al.* 2001a). Conversely, AKT1^{Myr} mice, regardless of sex, exhibited non-fasted hyperglycemia at weaning. There was an increase in severity with time as fasted hyperglycemia was not detectable until 5 months of age. To confirm that the hyperglycemia was due to the *Akt1*^{Myr} transgene expression, doxycycline was administered to the mice to turn off the transgene. Doxycycline treatment reduced AKT1^{Myr} blood glucose to WT levels, confirming that the fasted and non-fasted hyperglycemia in AKT1^{Myr} mice was due to AKT1 hyperactivation. Other possible contributing factors, such as weight and food intake, were ruled out, further distinguishing the AKT1^{Myr} mice from the lighter AKT2^{KO} mice (Garofalo *et al.* 2003) and heavier obese diabetic mouse models (i.e. *db/db*, NZO, and TALLYHO mice) (Herberg *et al.* 1970, Coleman 1982, Kim *et al.* 2006).

Figure 4

Insulin resistance in the liver of AKT1^{Myr} mice. One week following the GTT, (B) an insulin tolerance test was performed ($n=5$). (A) Area under the curve ($P<0.04$). To analyze insulin signaling, mice were insulin-stimulated. Two minutes after injection, the mice were euthanized and the pancreas, (C) liver, (D) adipose tissue, and (E) skeletal muscle were collected and protein extracted and analyzed with insulin receptor (IR) total and IR (pY1158) ELISAs. All phospho-IR measurements were normalized to their total IR measurements.

(F) Homeostatic model assessment for insulin resistance (HOMA-IR) was calculated using the following measurements from the GTT: (fasted glucose $\times$ fasted insulin)/405. Data represented as mean $\pm$ s.e.m. Unpaired Student's *t*-tests were used to analyze differences in the insulin tolerance tests time points. One-way ANOVA followed by Student's *t*-tests within groups were used to analyze the data for A, C, D, E and F. Letters were used to illustrate significance as multiple groups are being compared (see the 'Materials and methods' section for explanation).

GTT was performed at 12 weeks to analyze the ability of AKT1^{Myr} mice to clear glucose from the blood. While both models exhibited glucose intolerance, serum insulin and glucagon levels measured during the GTT revealed that the molecular mechanisms driving the deregulations were different. As previously reported (Cho *et al.* 2001a, Garofalo *et al.* 2003), AKT2^{KO} mice had hyperinsulinemia, which was evident before the glucose injection and 45 min after the injection. Ultimately, the AKT2^{KO} mice

model a classic, insulin-based deregulation, in which early insulin resistance leads to compensatory hyperinsulinemia and eventually late insulin deficiency (Matthaei *et al.* 2000). When compared to WT mice, AKT1^{Myr} mice did not have elevated fasted insulin levels. However, insulin levels were significantly higher 45 min after the injection. This increase in insulin secretion may be β -cell compensation and may have occurred in response to the hyperglycemia also observed at this time point. This suggests that the

Figure 5

Decreased pancreas and islet size, with aging, in AKT1^{Myr} mice. Pancreas size was measured upon euthanization and dissection using a digital scale ($n=5$) in (A) 12-week- and (B) 16-month- ($P=0.0049$) old mice. Islet size ($n=50$ islets) was also measured at (C) 12 weeks and (D) 16 months ($P=0.008$). Islet diameter was determined analyzing H&E stained sections

through Axio Imaging Software. Unpaired Student's *t*-tests were used to analyze A, B, C and D. Data represented as mean $\pm$ s.e.m. Letters were used to illustrate significance as multiple groups are being compared (see the 'Materials and methods' section for explanation).

elevated blood glucose levels were not due to a lack of insulin production or secretion, but reduced insulin sensitivity (Weir & Bonner-Weir 2004).

While insulin deregulations are well studied, glucagon deregulations have been acknowledged but relatively ignored. Glucagon, which is secreted by pancreatic α -cells when blood glucose levels are low, is known as the antagonist to insulin. When glucagon binds to its receptor it activates cellular cAMP and protein kinase A (PKA) signaling to induce hepatic gluconeogenesis and glycogenolysis restoring glucose homeostasis during fasting (Moon & Won 2015). Increased PKA activity impairs glucose stimulated insulin secretion (GSIS), which is needed to prevent the immediate secretion and glucose-disposing action of insulin (Song *et al.* 2014). Serum glucagon levels in AKT2^{KO} mice were similar to WT mice. However, AKT1^{Myr} mice had significantly elevated fasted glucagon levels, which returned to WT levels by the 45-min time point, most likely due to the surge in insulin secretion.

Fasted hyperglucagonemia, as seen in AKT1^{Myr} mice, has been observed in diabetic patients (Unger *et al.* 1970, Baron *et al.* 1987, Reaven *et al.* 1987) and linked to the manifestation of fasted hyperglycemia and glucose intolerance. The mechanisms behind hyperglucagonemia are still relatively unclear, but it has been shown to result from the inadequate response of α -cells to elevated blood glucose levels (Rizza 2010). This α -cell dysfunction leads to hepatic insulin resistance (Basu *et al.* 2004a), causing non-fasted hyperglycemia by preventing the suppression of endogenous glucose production during a meal, and fasted hyperglycemia via chronically elevated endogenous glucose production (Firth *et al.* 1986, Basu *et al.* 2000). The hyperglucagonemia-induced hepatic insulin resistance also significantly decreases hepatic glucose uptake and disposal due to impaired glucokinase activity (Wajngot *et al.* 1991, Caro *et al.* 1995). This impaired hepatic glucose metabolism has been identified in mild and severe diabetes patients making it an early contributing event in the pathogenesis of diabetes and not simply an effect (Basu *et al.* 2004b, Bock *et al.* 2007).

One week following the GTT, an insulin tolerance test was performed to analyze the sensitivity of insulin-responsive tissues in AKT1^{Myr} mice. AKT1^{Myr} mice and WT mice were not significantly different when comparing the area under the curve, suggesting an absence of insulin resistance. However, at the 15-min time point the AKT1^{Myr} mice had significantly higher blood glucose levels than the WT mice, suggesting there may be altered insulin signaling causing this delay in insulin response. Further analysis of

liver tissue revealed significantly decreased IR phosphorylation in AKT1^{Myr} mice, compared to WT mice, despite no significant difference in IR levels. This decrease in IR activation explains the delay in insulin response seen early in the ITT and the inability of AKT1^{Myr} mice to aptly clear glucose from the blood. Further calculation of the HOMA-IR confirmed insulin resistance in AKT1^{Myr} mice, as compared to WT mice. However, at 12 weeks, this resistance is not as severe as the resistance seen in AKT2^{KO} mice.

Additional longevity studies must be performed to determine whether the insulin resistance worsens with age, but analysis of pancreas and islet size suggests a gradual loss of β -cell mass. This loss of β -cell mass, evident by a decrease in total pancreas size and islet diameter, is typically indicative of long-term insulin resistance and β -cell failure due to chronic hyperinsulinemia and hyperglycemia (Prentki & Nolan 2006). There also appears to be an age-induced increase in islet diameter of WT mice. This is most likely due to naturally occurring β -cell compensation or the presence of islet adenomas, which also develop naturally in about 33% of our aged WT mice.

In this study, we characterized the pre-tumor, prediabetic phenotype of AKT1^{Myr} mice, which exhibit non-fasted hyperglycemia as early as weaning and fasted hyperglycemia by 5 months of age, regardless of sex. Based upon previous findings, this hyperglycemia is likely due to α -cell dysfunction, specifically hyperglucagonemia. Although the mechanisms behind hyperglucagonemia are still relatively unclear, we are proposing that AKT1^{Myr} mice, with fasted hyperglucagonemia, have impaired GSIS, resulting in glucose intolerance despite increased compensatory insulin secretion. Hepatic insulin resistance, an additional factor, may exacerbate the problem, preventing normoglycemia via increased hepatic glucose production and decreased hepatic glucose storage. As the fasted and non-fasted hyperglycemias are reversible when the Akt1^{Myr} transgene is suppressed, we have attributed this diabetic phenotype to the constitutive activation of AKT1 in the pancreas of this mouse model. Collectively, this pre-diabetic model highlights a novel glucagon-mediated mechanism by which AKT1 hyperactivation affects glucose homeostasis and provides a means to better delineate molecular mechanisms contributing to diabetes mellitus and perhaps future association between diabetes and a subset of pancreatic cancers.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work was supported by the National Cancer Institute (NCI) grant R21 (CA129302 to D A A); the University of Central Florida (UCF) Gerontology Applied Research Fellowship from the Learning Institute for Elders at UCF (MEDI00041); the Florida Ladies Auxiliary to the Veterans of Foreign Wars (MEDI000177); the UCF Burnett School of Biomedical Sciences (BSBS) Startup Funds (20070716), and the National Institute on Aging (AG032290 to M M M). T M A was supported in part by a McKnight Graduate Fellowship provided by the Florida Education Fund.

Author contribution statement

T M A designed the study, performed all of the experiments, and prepared this manuscript. V P assisted in all of the metabolism studies (GTT, ITT, and insulin stimulation). L P S assisted with breeding, weaning, genotyping, and glucose testing. M M M served as an expert consultant on all metabolism experiments. D A A, the corresponding author, provided financial support and supervised the project. All authors were involved in the editing of this manuscript.

Acknowledgements

R21 CA129302 supported the initial studies of glucose deregulation. Completion of the work was supported by donations from the Learning Institute for Elders at UCF and the Florida Ladies Auxiliary to the Veterans of Foreign Wars. BSBS shared core equipment resources for histology, and UCF animal care facilities were used for this study.

References

- Albury TM, Pandey V, Gitto SB, Dominguez L, Spinel LP, Talarchek J, Klein-Szanto AJ, Testa JR & Altomare DA 2015 Constitutive activation of Akt1 cooperates with KRasG12D to accelerate *in vivo* pancreatic tumor onset and progression. *Neoplasia* **17** 175–183. (doi:10.1016/j.neo.2014.12.006)
- Altomare DA & Testa JR 2005 Perturbations of the AKT signaling pathway in human cancer. *Oncogene* **24** 7455–7464. (doi:10.1038/sj.onc.1209085)
- Baron AD, Schaeffer L, Shragg P & Kolterman OG 1987 Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. *Diabetes* **36** 274–283. (doi:10.2337/diab.36.3.274)
- Basu A, Basu R, Shah P, Vella A, Johnson CM, Nair KS, Jensen MD, Schwenk WF & Rizza RA 2000 Effects of type 2 diabetes on the ability of insulin and glucose to regulate splanchnic and muscle glucose metabolism: evidence for a defect in hepatic glucokinase activity. *Diabetes* **49** 272–283. (doi:10.2337/diabetes.49.2.272)
- Basu R, Basu A, Johnson CM, Schwenk WF & Rizza RA 2004a Insulin dose–response curves for stimulation of splanchnic glucose uptake and suppression of endogenous glucose production differ in nondiabetic humans and are abnormal in people with type 2 diabetes. *Diabetes* **53** 2042–2050. (doi:10.2337/diabetes.53.8.2042)
- Basu R, Schwenk WF & Rizza RA 2004b Both fasting glucose production and disappearance are abnormal in people with “mild” and “severe” type 2 diabetes. *American Journal of Physiology. Endocrinology and Metabolism* **287** E55–E62. (doi:10.1152/ajpendo.00549.2003)
- Bates H, Sirek A, Kiraly M, Yue J, Riddell M, Matthews S & Vranic M 2008 Adaptation to intermittent stress promotes maintenance of β -cell compensation: comparison with food restriction. *American Journal of Physiology. Endocrinology and Metabolism* **295** E947–E958. (doi:10.1152/ajpendo.90378.2008)
- Bernal-Mizrachi E, Wen W, Stahlhut S, Welling CM & Permutt MA 2001 Islet β cell expression of constitutively active Akt1/PKB α induces striking hypertrophy, hyperplasia, and hyperinsulinemia. *Journal of Clinical Investigation* **108** 1631–1638. (doi:10.1172/JCI200113785)
- Bock G, Chittilapilly E, Basu R, Toffolo G, Cobelli C, Chandramouli V, Landau BR & Rizza RA 2007 Contribution of hepatic and extrahepatic insulin resistance to the pathogenesis of impaired fasting glucose: role of increased rates of gluconeogenesis. *Diabetes* **56** 1703–1711. (doi:10.2337/db06-1776)
- Caro JF, Triester S, Patel VK, Tapscott EB, Frazier NL & Dohm GL 1995 Liver glucokinase: decreased activity in patients with type II diabetes. *Hormone and Metabolic Research* **27** 19–22. (doi:10.1055/s-2007-979899)
- Chen WS, Peng XD, Wang Y, Xu PZ, Chen ML, Luo Y, Jeon SM, Coleman K, Haschek WM, Bass J *et al.* 2009 Leptin deficiency and β -cell dysfunction underlie type 2 diabetes in compound Akt knockout mice. *Molecular and Cellular Biology* **29** 3151–3162. (doi:10.1128/MCB.01792-08)
- Cheung M & Testa JR 2013 Diverse mechanisms of AKT pathway activation in human malignancy. *Current Cancer Drug Targets* **13** 234–244. (doi:10.2174/1568009611313030002)
- Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw EB, Kaestner KH, Bartolomei MS, Shulman GI & Birnbaum MJ 2001a Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB β). *Science* **292** 1728–1731. (doi:10.1126/science.292.5522.1728)
- Cho H, Thorvaldsen JL, Chu Q, Feng F & Birnbaum MJ 2001b Akt1/PKB α is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. *Journal of Biological Chemistry* **276** 38349–38352. (doi:10.1074/jbc.C100462200)
- Coleman DL 1982 Diabetes-obesity syndromes in mice. *Diabetes* **31** 1–6. (doi:10.2337/diab.31.1.S1)
- Cummings B, Digitale E, Stanhope K, Graham J, Baskin D, Reed B, Sweet I, Griffen S & Havel PJ 2008 Development and characterization of a novel rat model of type 2 diabetes mellitus: the UC Davis type 2 diabetes mellitus UCD–T2DM rat. *American Journal of Physiology. Regulatory, Integrative and Comparative Physiology* **295** 1782–1793. (doi:10.1152/ajpregu.90635.2008)
- Firth RG, Bell PM, Marsh HM, Hansen I & Rizza RA 1986 Postprandial hyperglycemia in patients with noninsulin-dependent diabetes mellitus. Role of hepatic and extrahepatic tissues. *Journal of Clinical Investigation* **77** 1525–1532. (doi:10.1172/JCI112467)
- Garofalo RS, Orena SJ, Rafidi K, Torchia AJ, Stock JL, Hildebrandt AL, Coskran T, Black SC, Brees DJ, Wicks JR *et al.* 2003 Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB β . *Journal of Clinical Investigation* **112** 197–208. (doi:10.1172/JCI16885)
- Grote CW, Groover AL, Ryals JM, Geiger PC, Feldman EL & Wright DE 2013 Peripheral nervous system insulin resistance in *ob/ob* mice. *Acta Neuropathologica Communications* **1** 1–11. (doi:10.1186/2051-5960-1-15)
- Hale MA, Kagami H, Shi L, Holland AM, Elsässer HP, Hammer RE & MacDonald RJ 2005 The homeodomain protein PDX1 is required at mid-pancreatic development for the formation of the exocrine pancreas. *Developmental Biology* **286** 225–237. (doi:10.1016/j.ydbio.2005.07.026)
- Hay N 2011 Akt isoforms and glucose homeostasis – the leptin connection. *Trends in Endocrinology and Metabolism* **22** 66–73. (doi:10.1016/j.tem.2010.09.003)
- Hemmings BA & Restuccia DF 2012 PI3K–PKB/Akt pathway. *Cold Spring Harbor Perspectives in Biology* **4** 1–3. (doi:10.1101/cshperspect.a011189)
- Herberg L, Major E, Hennigs U, Grünekle D, Freytag G & Gries FA 1970 Differences in the development of the obese–hyperglycemic syndrome in *obob* and *NZO* mice. *Diabetologia* **6** 292–298. (doi:10.1007/BF01212241)

- Holland AM, Hale MA, Kagami H, Hammer RE & MacDonald RJ 2002 Experimental control of pancreatic development and maintenance. *PNAS* **99** 12236–12241. (doi:10.1073/pnas.192255099)
- Kim JH, Stewart TP, Soltani-Bejnood M, Wang L, Fortuna JM, Mostafa OA, Moustaid-Moussa N, Shohieb AM, McEntee MF, Wang Y *et al.* 2006 Phenotypic characterization of polygenic type 2 diabetes in TALLYHO/JngJ mice. *Journal of Endocrinology* **191** 437–446. (doi:10.1677/joe.1.06647)
- Kushner JA, Simpson L, Wartschow LM, Guo S, Rankin MM, Parsons R & White MF 2005 Phosphatase and tensin homolog regulation of islet growth and glucose homeostasis. *Journal of Biological Chemistry* **280** 39388–39393. (doi:10.1074/jbc.M504155200)
- Matthaei S, Stumvoll M, Kellerer M & Häring HU 2000 Pathophysiology and pharmacological treatment of insulin resistance. *Endocrine Reviews* **21** 585–618. (doi:10.1210/edrv.21.6.0413)
- Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, Piemonti L, Capurso G, Di Florio A, delle Fave G *et al.* 2010 Pancreatic endocrine tumors: expression profiling evidences a role for AKT–mTOR pathway. *Journal of Clinical Oncology* **28** 245–255. (doi:10.1200/JCO.2008.21.5988)
- Moon JS & Won KC 2015 Pancreatic α -cell dysfunction in type 2 diabetes: old kids on the block. *Diabetes & Metabolism Journal* **39** 1–9. (doi:10.4093/dmj.2015.39.1.1)
- Prentki M & Nolan CJ 2006 Islet β cell failure in type 2 diabetes. *Journal of Clinical Investigation* **116** 1802–1812. (doi:10.1172/JCI29103)
- Reaven GM, Chen YD, Golay A, Swislocki AL & Jaspan JB 1987 Documentation of hyperglucagonemia throughout the day in non-obese and obese patients with noninsulin-dependent diabetes mellitus. *Journal of Clinical Endocrinology and Metabolism* **64** 106–110. (doi:10.1210/jcem-64-1-106)
- Rizza RA 2010 Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy. *Diabetes* **59** 2697–2707. (doi:10.2337/db10-1032)
- Schlieman MG, Fahy BN, Ramsamooj R, Beckett L & Bold RJ 2003 Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. *British Journal of Cancer* **89** 2110–2115. (doi:10.1038/sj.bjc.6601396)
- Song WJ, Mondal P, Wolfe A, Alonso LC, Stamateris R, Ong BW, Lim OC, Yang KS, Radovick S, Novaira HJ *et al.* 2014 Glucagon regulates hepatic kisspeptin to impair insulin secretion. *Cell Metabolism* **19** 667–681. (doi:10.1016/j.cmet.2014.03.005)
- Stiles BL, Kuralwalla-Martinez C, Guo W, Gregorian C, Wang Y, Tian J, Magnuson MA & Wu H 2006 Selective deletion of Pten in pancreatic β cells leads to increased islet mass and resistance to STZ-induced diabetes. *Molecular and Cellular Biology* **26** 2772–2781. (doi:10.1128/MCB.26.7.2772-2781.2006)
- Tschopp O, Yang ZZ, Brodbeck D, Dummler BA, Hemmings-Mieszczak M, Watanabe T, Michaelis T, Frahm J & Hemmings BA 2005 Essential role of protein kinase B γ (PKB γ /Akt3) in postnatal brain development but not in glucose homeostasis. *Development* **132** 2943–2954. (doi:10.1242/dev.01864)
- Tuttle RL, Gill NS, Pugh W, Lee JP, Koeberlein B, Furth EE, Polonsky KS, Naji A & Birnbaum MJ 2001 Regulation of pancreatic β -cell growth and survival by the serine/threonine protein kinase Akt1/PKB α . *Nature Medicine* **7** 5–14. (doi:10.1038/nm1001-1133)
- Unger RH, Aguilar-Parada E, Müller WA & Eisentraut AM 1970 Studies of pancreatic α cell function in normal and diabetic subjects. *Journal of Clinical Investigation* **49** 837–848. (doi:10.1172/JCI106297)
- Wajngot A, Chandramouli V, Schumann WC, Efendic S & Landau BR 1991 Quantitation of glycogen/glucose-1-P cycling in liver. *Metabolism* **40** 877–881. (doi:10.1016/0026-0495(91)90019-S)
- Weir GC & Bonner-Weir S 2004 Five stages of evolving β -cell dysfunction during progression to diabetes. *Diabetes* **53** 16–21. (doi:10.2337/diabetes.53.suppl_3.S16)

Received in final form 2 October 2015

Accepted 20 October 2015

Accepted Preprint published online 20 October 2015